Pablo Corral Shares New Insights: Genome Editing and Gene Therapy for Lipid Disorders
Pablo Corral, Past President of Argentine Lipid Society, has shared a post on LinkedIn:
“A must read article
‘Gene therapy and genome editing for lipoprotein disorders‘ provides a comprehensive and timely overview of how advances in genetic medicine—including AAV gene addition, CRISPR editing, and RNA-based strategies—are reshaping the prevention and management of dyslipidaemias and ASCVD.
This open-access article highlights how innovative approaches may overcome limitations of lifelong lipid-lowering therapy, address unmet clinical needs in familial and polygenic disorders, and integrate polygenic risk scores and machine learning to personalize cardiovascular prevention.
An excellent resource for clinicians, researchers, and students interested in the rapidly evolving field of cardiovascular genetics.”
Title: Gene therapy and genome editing for lipoprotein disorders
Authors: Chen Gurevitz, Archna Bajaj, Amit V Khera, Ron Do, Heribert Schunkert, Kiran Musunuru, Robert S Rosenson
Read the full paper here.
Stay informed with Hemostasis Today.
-
Aug 26, 2026, 14:03Ahmad Masri: The Amyloid Depleter Revolution in ATTR-CM
-
Aug 26, 2026, 13:59David McIntosh: Immunoglobulin Stewardship in the Face of Rising Demand
-
Aug 26, 2026, 13:54Giuseppe Biondi Zoccai: Congratulations to the Next Editor-in-Chief of the EHJ
-
Aug 26, 2026, 13:25Omar Adwan: Abnormal Nuclear Morphology of Neutrophil
-
Aug 26, 2026, 13:05Preventing Thrombosis with WTDay26
-
Aug 26, 2026, 10:09Gemma Figtree: How Well Do We Predict Heart Attack Risk in Women?
-
Aug 26, 2026, 10:06Understanding and Managing Fatigue in ITP – ITP Support Association
-
Aug 26, 2026, 10:04Abdul Muqtadir Abbasi: When a High INR Hides a Thrombotic Cancer
-
Aug 26, 2026, 09:42Mohammed Alo: What’s Wrong With the New Blood Pressure Guidelines?